The Drugs.com Monthly Update Podcast

Welcome to the June 2026 edition of Drugs.com Monthly Update, where we provide you with some of the latest FDA approvals. This episode uses AI tools to help with formatting, organisation, and narration. All content has been reviewed by a senior editorial pharmacist.

This month, we're exploring advances across multiple therapeutic areas. We’ll discuss Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers. Let's delve into how these developments are poised to enhance patient care.

Our first topic is Lumvoa, spelled L-U-M-V-O-A, an exciting new treatment for thyroid eye disease, or TED. TED is a rare and debilitating autoimmune disorder often linked to Graves disease, leading to symptoms like eye bulging, pain, and vision disturbances. Traditionally challenging to manage, TED now has a promising new option with Lumvoa, an insulin-like growth factor-1 receptor inhibitor. Clinically tested in the THRIVE and THRIVE-2 trials, Lumvoa showed significant improvements in the signs and symptoms of TED, with some patients noticing proptosis reductions as early as three weeks. Lumvoa is administered intravenously every three weeks for a total of 5 infusions. However, patients should be aware of potential adverse effects such as muscle spasms, headache, and more serious risks like hyperglycemia and hearing impairment.

Next, we shift focus to Utebzi, spelled U-T-E-B-Z-I, the first oral carbapenem antibiotic approved in the U.S. for complicated urinary tract infections, including pyelonephritis. Such infections demand effective treatment options due to their potential severity and resistance to other drugs. Utebzi offers a convenient oral alternative to traditional IV treatments, achieving comparable efficacy in the PIVOT-PO Phase 3 trial. Taken as two 300 mg tablets every six hours, it provides a patient-friendly option for those with limited treatment alternatives. Important to note for prescribers and patients alike, Utebzi should not be used in patients with carnitine deficiency or those allergic to beta-lactam antibiotics, and it carries a risk of seizures when used with certain medications like valproic acid.

Finally, we introduce Tregzi, spelt T-R-E-G-Z-I, a donor stem cell transplant used in adults with blood cancers (hematological malignancies). Tregzi is used for rebuilding the blood and immune system and lowering the risk of moderate to severe chronic graft-versus-host disease. Tregzi is given as a series of three infusions over two to three days in hospital, after a conditioning regime. Important side effects to be aware of are graft failure, graft-versus-host disease, new or secondary cancers, infectious disease and infusion reactions.

Thank you for tuning in to the Drugs.com monthly update podcast, where staying informed means staying ahead in your field. We look forward to bringing you more updates next month. Until next time, know more, be sure.